The Board of Directors of BOAN BIOTECH (06955) has been notified by its controlling shareholder, LUYE PHARMA Group, that, pursuant to the terms of a subscription agreement related to exchangeable preferred shares, an arrangement is planned. LUYE PHARMA's wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., intends to further transfer 38.5 million H shares on the market to the issuer, Luye Geneora Holding Limited, on January 22, 2026, as part of the proposed transfer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments